Monsanto Technology LLC v. Nuziveedu Seeds Ltd.
Rule established
The question of whether patents on transgenic plant varieties and seeds are excluded under Section 3(j) requires trial; patent rights cannot be negated at interlocutory stage
Facts
- Monsanto held Indian Patent No. 214436 for a nucleic acid sequence encoding the Cry2Ab insecticidal protein (Bt gene) used in transgenic cotton
- Monsanto licensed this technology to Indian seed companies including Nuziveedu Seeds Ltd. through sub-licence agreements
- Disputes arose over licence fees (trait value); Nuziveedu terminated the agreements and continued using the technology
- Monsanto filed for patent infringement; Nuziveedu defended by arguing the patent was invalid under Section 3(j)
- The Delhi High Court Division Bench held that once the patented gene was inserted into a plant, the resulting seed/plant fell within Section 3(j)
Issue
- Whether a patent on a nucleic acid sequence (Bt gene) is excluded from patentability under Section 3(j) of the Patents Act, 1970 on the ground that the gene, once inserted into a plant, becomes part of a "plant or animal" or "essentially biological process."
Held
- The Division Bench erred in deciding the question of Section 3(j) applicability at the interlocutory stage without a full trial
- The question is a complex mixed question of fact and law requiring trial
- The Supreme Court set aside the Division Bench order and restored the Single Judge's order
- The matter was remitted for trial on merits
- The Court did not express any opinion on whether Section 3(j) applies to the patent
Ratio Decidendi
The question of whether a patent claiming a nucleic acid sequence is excluded under Section 3(j) when that sequence is incorporated into a plant variety is a complex question that cannot be determined at an interlocutory stage. The interaction between patent rights in a gene construct and the exclusion of plants, animals, and essentially biological processes from patentability requires a full trial with evidence.
How to use it in an exam
- Deploy when discussing the intersection of patent law and plant variety protection
- Use to illustrate the unresolved tension between gene patents and Section 3(j) exclusion
- Contrast with Diamond v. Chakrabarty (US approach allowing patents on living organisms)
- Key line: "The complex questions involved in the interplay between the Patents Act and the PPVFR Act require evidence and cannot be decided in interlocutory proceedings."
Source
Source: (2019) 3 SCC 381; verified via SCC Online
This is an educational summary, not the judgment itself. Cite the reported version in professional or academic work.